Innovative Diagnostic Platform Visby Medical's proprietary, instrument-free, single-use PCR platform offers rapid and accurate testing for respiratory and sexually transmitted infections, making it highly attractive for healthcare providers seeking efficient, point-of-care diagnostics.

Strategic Partnerships The company’s recent collaboration with Google to enable at-home testing expands its reach into the consumer and telehealth markets, presenting new opportunities to sell more testing devices and expand distribution channels.

Growing Funding & Validation With over 55 million dollars raised in recent funding rounds and FDA clearance for key tests, Visby is well-positioned to scale its production and sales efforts, especially targeting hospitals, clinics, and public health agencies.

Focus on Antibiotic Resistance Targeting antibiotic-resistant bacteria through specialized rapid PCR tests, supported by grants from organizations like CARB-X, paves the way for sales to public health sectors and laboratories focused on combating antibiotic resistance.

Market Differentiation Compared to larger competitors like Roche and Cepheid, Visby’s innovative technology and recent product approvals create a compelling value proposition for healthcare providers seeking compact, rapid, and reliable diagnostic solutions.